Movement Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 10, 2021.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending September 4, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

This was the first time that progression of cognitive fluctuations in patients with Lewy body dementia had been systematically investigated using a clinical rating scale.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 27, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Adolfo Ramirez-Zamora, MD.

At weeks 54, 106, and 145, most of both age groups achieved treatment success on both the CGIC and PGIC, with numerically higher percentages observed in younger vs older participants.

Here's what is coming soon to NeurologyLive.

Tardive dyskinesia can present many challenges in its treatment and can be difficult to differentiate from similar disorders.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

Investigators found that phase advance was associated with late-stage PD, mostly due to active offset advance, amplitude reduction, and weakened robustness.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

The investigational agent NOE-105 has previously been found safe for treating adults with Tourette syndrome at 30-mg daily doses.

Investigators obtained a molecular diagnostic yield of 39% in 66 sequential, unselected individuals with diverse presentations of rare neurogenetic disorders when using a model that integrates additional assays.

Here's what is coming soon to NeurologyLive.

Panelists look ahead in the management of advanced Parkinson disease and discuss the promise of different investigational therapies.

A discussion about the benefits of a multidisciplinary evaluation for patients with advanced Parkinson disease who are potential candidates for device-assisted therapy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 6, 2021.

Homeostatic equilibrium was achieved with CNM-Au8 across essential energetic metabolites, including adenosine triphosphate, intracellular phosphorous, phosphocholine, and phosphorylation potential index.

The model discovered nonsequential, overlapping disease progression trajectories, supporting the use of nondeterministic disease progression models.

Here's what is coming soon to NeurologyLive.

Michael J. Soileau, MD, discusses the challenges of starting a device-assisted therapy in patients with advanced Parkinson disease.

An advanced Parkinson disease expert explains how to discuss the different device-assisted therapy options with patients.

AC Immune, the company presenting the data at the 2021 AAIC meeting, also recently acquired an a-syn vaccine, Affiris PD01.